Autolus Therapeutics plc

NasdaqGS:AUTL Stock Report

Market Cap: US$745.1m

Autolus Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Autolus Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-73.9%

Buyback Yield

Total Shareholder Yield-73.9%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 21

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Sep 06

Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Autolus Therapeutics: Major Inflection Point On The Horizon

Jul 31

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

May 14

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09
We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12
Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Dec 15
We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AUTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AUTL's dividend payments have been increasing.


Dividend Yield vs Market

Autolus Therapeutics Dividend Yield vs Market
How does AUTL dividend yield compare to the market?
SegmentDividend Yield
Company (AUTL)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Biotechs)2.3%
Analyst forecast (AUTL) (up to 3 years)0%

Notable Dividend: Unable to evaluate AUTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AUTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate AUTL's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AUTL has not reported any payouts.


Discover strong dividend paying companies